OTTAWA, Ontario, November 12, 2019 (Newswire.com) – Orion Biotechnology Canada Ltd. today announced that Dr. Thomas Hecht has been appointed Chairman of its Board of Directors. Dr. Hecht brings extensive expertise in leading value creation processes
OTTAWA, Ontario, October 31, 2019 (Newswire.com) – Orion Biotechnology Canada, Ltd. today announced that OB-002 was able to significantly reduce bone metastasis in a murine model of breast cancer. The study was conducted in collaboration with
OTTAWA, Canada, August 6, 2019 (Newswire.com) – Orion Biotechnology Canada Ltd. today announced that Sir Gregory Winter FRS has agreed to chair the Orion Biotechnology Scientific Advisory Board (SAB). Sir Gregory Winter FRS is a
OTTAWA, Ontario, July 23, 2019 (Newswire.com) – Orion Biotechnology Canada Ltd. today announced that In vitro potency assessment of their lead compound, OB-002, has demonstrated that the chemokine analogue is more potent than other CCR5
OTTAWA, Ontario, July 2, 2019 (Newswire.com) – Orion Biotechnology Canada Ltd., today announced the publication of preclinical data evaluating the efficacy of OB-002 (5P12-RANTES) in a murine model of multiple sclerosis in Science Translation Medicine
OTTAWA, Ontario, June 20, 2019 (Newswire.com) – Orion Biotechnology Canada Ltd., today announced new preclinical data evaluating the efficacy of OB-002 (5P12-RANTES) in colorectal cancer. BALB/c mice were inoculated subcutaneously with the CT-26 colorectal cancer
343 Preston Street
11th floor,
Ottawa, On K1S 1N4
CANADA
Campus Biotech
Innovation Park
Avenue de Sécheron 15
1202 Genève
SWITZERLAND
Orion Biotechnology
PolandSP. Z.O.O.
UI Bobrzyńskiego 14
30-348 Krakôw
POLAND
CONTACT: info@orionbiotechnology.com
Leave us a message and we will try to respond by the next business day
343 Preston Street
11th floor,
Ottawa, ON K1S 1N4
CANADA
info@orionbiotechnology.com
Leave us a message and we will try to respond by the next business day
343 Preston Street
11th floor,
Ottawa, ON K1S 1N4
CANADA
info@orionbiotechnology.com
